Experienced in Essential Thrombocythemia

Dr. Monte F. Jones

Texas Oncology PA
Mckinney, TX
Experienced
in Essential Thrombocythemia
Specialties:Hematology Oncology | Oncology | Hematology
Accepting New Patients
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Monte Jones is a Hematologist Oncology specialist and an Oncologist in Mckinney, Texas. Dr. Jones and is rated as an Experienced provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Factor V Leiden Thrombophilia, and Mediastinal Tumor. Dr. Jones is currently accepting new patients.

His clinical research consists of participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in TX
Hospital Affiliations
Baylor Scott And White Medical Center Mckinney
Medical Center Of Mckinney
Medical City Plano
Baylor Scott & White Medical Center - Centennial
Languages Spoken
English
Spanish
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Friday Health
  •  Scott and White Health
  •  Oscar
  •  UnitedHealthcare
  •  Humana

Locations

TEXAS ONCOLOGY PA
5236 W University Dr, Suite 1000, Mckinney, TX 75071
972-923-2600

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drugs: Imlunestrant, Exemestane, Fulvestrant, Abemaciclib
Study Phase: Phase 3
postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: December 09, 2024
Intervention Type: Drug
Study Drugs: Abemaciclib, Fulvestrant
Study Phase: Phase 3
Breast Cancer Index (BCI) Registry
Breast Cancer Index (BCI) Registry
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2024
Intervention Type: Diagnostic test
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 13, 2024
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
A Two-cohort, Phase 2 Study of FL-101 as Neoadjuvant Therapy in Patients With Surgically Resectable Non-Small Cell Lung Cancer
A Two-cohort, Phase 2 Study of FL-101 as Neoadjuvant Therapy in Patients With Surgically Resectable Non-Small Cell Lung Cancer
Enrollment Status: Withdrawn
Publish Date: January 11, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
Enrollment Status: Completed
Publish Date: November 04, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Enrollment Status: Terminated
Publish Date: September 11, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
Enrollment Status: Withdrawn
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 8 Less Clinical Trials
Similar Doctors
Expertise in
7
conditions
Dr. Ofobuike N. Okani
Hematology Oncology | Oncology | Hematology
Expertise in
7
conditions
Dr. Ofobuike N. Okani
Hematology Oncology | Oncology | Hematology

Texas Oncology PA

10425 N Central Expy, 
Dallas, TX 
 (23.5 mi)
214-361-2025
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ofobuike Okani is a Hematologist Oncology specialist and an Oncologist in Dallas, Texas. Dr. Okani and is rated as an Advanced provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Essential Thrombocythemia, Breast Cancer, Paget Disease of the Breast, Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Okani is currently accepting new patients.

Expertise in
13
conditions
Dr. Sharad K. Jain
Hematology Oncology | Oncology | Hematology
Expertise in
13
conditions
Dr. Sharad K. Jain
Hematology Oncology | Oncology | Hematology

Texas Oncology PA

2600 Scripture St, 
Denton, TX 
 (28.0 mi)
940-382-1022
Languages Spoken:
English, Hindi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Sharad Jain is a Hematologist Oncology specialist and an Oncologist in Denton, Texas. Dr. Jain and is rated as a Distinguished provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Essential Thrombocythemia, Breast Cancer, Paget Disease of the Breast, and Anemia. Dr. Jain is currently accepting new patients.

Expertise in
69
conditions
Dr. Meera S. Shreedhara-Vasudha
Oncology | Hematology Oncology
Expertise in
69
conditions
Dr. Meera S. Shreedhara-Vasudha
Oncology | Hematology Oncology

Texas Oncology PA

4215 Joe Ramsey Blvd, 
Greenville, TX 
 (33.0 mi)
903-408-5112
Languages Spoken:
English, French, Hindi, Punjabi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Meera Shreedhara-Vasudha is an Oncologist and a Hematologist Oncology provider in Greenville, Texas. Dr. Shreedhara-Vasudha and is rated as a Distinguished provider by MediFind in the treatment of Essential Thrombocythemia. Her top areas of expertise are Leukocytosis, Paris-Trousseau Thrombocytopenia, RUNX1 Familial Platelet Disorder, and Paget Disease of the Breast. Dr. Shreedhara-Vasudha is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile